drugset / Trial / NCT00705406

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406

Phase 2 Completed 405 enrolled BioCryst Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PERAMIVIR ANHYDROUS Small molecule 600 mg Intramuscular

Indications